On Tuesday, October 11, I Bought 30 shares of
AbbVie Inc. at $ 62.98 per share plus commission.
AbbVie Inc. discovers, develops, manufactures, and sells
pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy
administered as a subcutaneous injection to treat autoimmune diseases;
IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia;
and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for
adults with genotype 1 chronic hepatitis, including those with compensated
cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other
anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1
patients; Norvir, a protease inhibitor indicated in combination with other
antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory
syncytial virus infection in high risk infants. In addition, the company offers
AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic
low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic
insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the
palliative treatment of prostate cancer, and endometriosis and central
precocious puberty, as well as for the treatment of patients with anemia.
Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to
treat Parkinsons disease; Sevoflurane, an anesthesia product for human use;
TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by
high cholesterol and/or high triglycerides; and Zemplar to treat secondary
hyperparathyroidism. The company sells its products to wholesalers,
distributors, government agencies, health care facilities, specialty
pharmacies, and independent retailers from its distribution centers and public
warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics;
Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos
NV; and Alvine Pharmaceuticals, Inc. The company is headquartered in North
Chicago, Illinois and was spun off from Abbott Laboratories (ABT) in January
2013.
